TrueBlue (TBI) analyst forecast and price target
Analyst forecast
Consensus of 2 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| BMO Capital | Maintained | Outperform | $6.00 from $8.00 | Nov 5, 2025 |
| BMO Capital | Maintained | Outperform | $8.00 from $7.00 | Aug 6, 2025 |
| BMO Capital | Maintained | Outperform | $10.00 from $11.00 | Nov 5, 2024 |
| BMO Capital | Maintained | Outperform | $12.00 from $13.00 | Aug 7, 2024 |
| BMO Capital | Maintained | Outperform | $13.00 | Jun 17, 2024 |
| BMO Capital | Maintained | Outperform | $13.00 from $15.00 | May 8, 2024 |
| Baird | Maintained | Outperform | $13.00 from $14.00 | May 7, 2024 |
| BMO Capital | Maintained | Outperform | $20.00 from $21.00 | Jul 26, 2023 |
| BMO Capital | Upgraded | Market Perform → Outperform | $20.00 from $18.00 | May 22, 2023 |
| BMO Capital | Maintained | Market Perform | $18.00 from $20.00 | Apr 26, 2023 |
| Baird | Maintained | Outperform | $20.00 from $21.00 | Apr 25, 2023 |
Frequently asked questions
Is TBI a buy, sell, or hold?
Analysts covering TrueBlue currently average a Buy rating: 1 buy, 1 hold and 0 sell, from 2 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on TBI?
On Nov 5, 2025, BMO Capital maintained TrueBlue at Outperform with a price target of $6.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.